{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T11:07:41Z","timestamp":1789124861488,"version":"build-2803163510"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"5","funder":[{"DOI":"10.13039\/100015291","name":"Royal Free London NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015291","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012360","name":"NHS England","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012360","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acquired carbapenemase-producing organisms (CPO), particularly acquired carbapenemase-producing Enterobacterales (CPE), pose a major public health challenge due to limited treatment options.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate associations between CPO positivity and ethnic group, Index of Multiple Deprivation (IMD) and healthcare exposure, and to apply a statistical model to quantify these relationships.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>A retrospective observational analysis of CPO cases identified at a London teaching hospital (2016\u20132023) was conducted. Microbiological, clinical and demographic data were reviewed. Cases were classified as hospital onset healthcare associated (HOHA), community onset healthcare associated (COHA) or community onset community associated (COCA). Socioeconomic status was assessed using IMD. Positive and negative cases were compared by medical specialty, age, sex and ethnicity. Odds ratios for risk factors were estimated, and a mixed-effects logistic regression model was applied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 679 CPO isolates were detected in 651 patients. OXA-48-like (56.1%) and NDM (38.9%) were the predominant carbapenemases. HOHA accounted for 42.1% of cases, COCA for 39% and COHA for 18.9%. Renal, vascular and liver specialties had the highest proportions of CPO-positive patients. Females had 0.8 times the odds of CPO positivity compared with males, and risk increased with age until mid-life. White British patients had 0.62 times the odds of CPO positivity compared with other ethnic groups. IMD analysis showed a bell-shaped distribution, with highest prevalence in mid-deprivation quintiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CPOs arise from both healthcare-associated and community pathways. Differentiating HOHA, COHA and COCA enhances understanding of local epidemiology and supports targeted infection-prevention strategies including medical specialties.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jacamr\/dlag200","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:30:00Z","timestamp":1788521400000},"source":"Crossref","is-referenced-by-count":0,"title":["Acquired carbapenemase-producing organisms in North London: health inequalities and healthcare associations, 2016\u20132023"],"prefix":"10.1093","volume":"8","author":[{"given":"Marie Anne","family":"Chattaway","sequence":"first","affiliation":[{"name":"Department of Microbiology, Royal Free Hospital, Royal Free London NHS Foundation Trust , Pond Street, London ,","place":["UK"]},{"name":"Gastrointestinal Bacteria Reference Unit, United Kingdom Health Security Agency , Colindale, London ,","place":["UK"]},{"name":"NIHR Health Protection Research Unit (HPRU) in Healthcare Associated Infections and Antimicrobial Resistance (AMR), University of Oxford , Oxford ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayoub","family":"Saei","sequence":"additional","affiliation":[{"name":"Statistical Unit, United Kingdom Health Security Agency , Colindale, London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ho","sequence":"additional","affiliation":[{"name":"Infection Prevention and Control Services, Royal Free London NHS Foundation Trust , Pond Street, London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Heaphy","sequence":"additional","affiliation":[{"name":"Infection Prevention and Control Services, Royal Free London NHS Foundation Trust , Pond Street, London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Pang","sequence":"additional","affiliation":[{"name":"Infection Prevention and Control Services, Royal Free London NHS Foundation Trust , Pond Street, London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Lester","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Royal Free Hospital, Royal Free London NHS Foundation Trust , Pond Street, London ,","place":["UK"]},{"name":"Antimicrobial Resistance & Healthcare Associated Infections, United Kingdom Health Security Agency , Colindale, London ,","place":["UK"]},{"name":"Division of Infection and Immunity, University College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien J F","family":"Mack","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Royal Free Hospital, Royal Free London NHS Foundation Trust , Pond Street, London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"2026091106234526900_dlag200-B1","author":"UKHSA"},{"key":"2026091106234526900_dlag200-B2","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1093\/cid\/cix893","article-title":"Carbapenemase-producing organisms: a global scourge","volume":"66","author":"Bonomo","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2026091106234526900_dlag200-B3","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1128\/CMR.05035-11","article-title":"Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions","volume":"25","author":"Tzouvelekis","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"2026091106234526900_dlag200-B4","author":"UKHSA"},{"key":"2026091106234526900_dlag200-B5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13756-018-0362-9","article-title":"Carbapenem non-susceptibility of Klebsiella pneumoniae isolates in hospitals from 2011 to 2016, data from the German Antimicrobial Resistance Surveillance (ARS)","volume":"7","author":"Koppe","year":"2018","journal-title":"Antimicrob Resist Infect Control"},{"key":"2026091106234526900_dlag200-B6","doi-asserted-by":"publisher","first-page":"e4521","DOI":"10.1093\/cid\/ciaa1464","article-title":"Changing epidemiology and decreased mortality associated with carbapenem-resistant Gram-negative bacteria, 2000-2017","volume":"73","author":"Babiker","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026091106234526900_dlag200-B7","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2024.1405390","article-title":"Understanding the burden of antibiotic resistance: a decade of carbapenem-resistant gram-negative bacterial infections in Italian intensive care units","volume":"15","author":"Scaglione","year":"2024","journal-title":"Front Microbiol"},{"key":"2026091106234526900_dlag200-B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2024.107769","article-title":"Global and regional burden of bloodstream infections caused by carbapenem-resistant Gram-negative bacteria in 2019: a systematic analysis from the MICROBE database","volume":"153","author":"Zha","year":"2025","journal-title":"Int J Infect Dis"},{"key":"2026091106234526900_dlag200-B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.infpip.2023.100298","article-title":"Clinical, microbiological characteristics and predictors of mortality in patients with carbapenemase-producing Enterobacterales bloodstream infections: a multicentre study","volume":"5","author":"Anton-Vazquez","year":"2023","journal-title":"Infect Prev Pract"},{"key":"2026091106234526900_dlag200-B10","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.cmi.2016.10.005","article-title":"Counting the cost of an outbreak of carbapenemase-producing Enterobacteriaceae: an economic evaluation from a hospital perspective","volume":"23","author":"Otter","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"2026091106234526900_dlag200-B11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jhin.2025.07.030","article-title":"Prevalence of carbapenem-resistant Enterobacterales in healthcare and community settings in the UK: a systematic review and meta-analysis","volume":"165","author":"Almadhoon","year":"2025","journal-title":"J Hosp Infect"},{"key":"2026091106234526900_dlag200-B12","volume-title":"Carbapenemase Producing Gram Negative Organisms in England Since October 2020:Quarterly Update Q4 2023","author":"UKHSA","year":"2025. :\/\/..\/\/\/------\/---------2020---4-2023."},{"key":"2026091106234526900_dlag200-B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2026.107898","article-title":"Carbapenem-resistant Enterobacterales across the UK: a nationwide study of carbapenemase testing and novel antimicrobial activity","volume":"67","author":"Baltas","year":"2026","journal-title":"Int J Antimicrob Agents"},{"key":"2026091106234526900_dlag200-B14","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.1017\/ash.2025.10177","article-title":"The impact of socioeconomic status on the prevalence of antimicrobial resistance in high-income nations: a systematic review","volume":"5","author":"Levitch","year":"2025","journal-title":"Antimicrob Steward Healthc Epidemiol"},{"key":"2026091106234526900_dlag200-B15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13756-022-01059-1","article-title":"Dimensions of poverty as risk factors for antimicrobial resistant organisms in Canada: a structured narrative review","volume":"11","author":"King","year":"2022","journal-title":"Antimicrob Resist Infect Control"},{"key":"2026091106234526900_dlag200-B16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001944","article-title":"Evidence for community transmission of community-associated but not health-care-associated methicillin-resistant Staphylococcus aureus strains linked to social and material deprivation: spatial analysis of cross-sectional data","volume":"13","author":"Tosas Auguet","year":"2016","journal-title":"PLoS Med"},{"key":"2026091106234526900_dlag200-B17","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40249-018-0459-7","article-title":"Investigating the impact of poverty on colonization and infection with drug-resistant organisms in humans: a systematic review","volume":"7","author":"Alividza","year":"2018","journal-title":"Infect Dis Poverty"},{"key":"2026091106234526900_dlag200-B18","author":"UKHSA"},{"key":"2026091106234526900_dlag200-B19","volume-title":"English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR): Report 2017 to 2021","author":"UKHSA","year":"2021"},{"key":"2026091106234526900_dlag200-B20","author":"RCPath"},{"key":"2026091106234526900_dlag200-B21","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1086\/677157","article-title":"Rising rates of carbapenem-resistant Enterobacteriaceae in community hospitals: a mixed-methods review of epidemiology and microbiology practices in a network of community hospitals in the Southeastern United States","volume":"35","author":"Thaden","year":"2014","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2026091106234526900_dlag200-B22","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.3390\/antibiotics12121699","article-title":"From epidemiology of community-onset bloodstream infections to the development of empirical antimicrobial treatment-decision algorithm in a region with high burden of antimicrobial resistance","volume":"12","author":"Chotiprasitsakul","year":"2023","journal-title":"Antibiotics"},{"key":"2026091106234526900_dlag200-B23","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlag099","article-title":"Carbapenemases: epidemiology, detection and management in a changing global landscape","volume":"8","author":"Macesic","year":"2026","journal-title":"JAC Antimicrob Resist"},{"key":"2026091106234526900_dlag200-B24","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1404404","article-title":"Clinical outcomes and risk factors for mortality in recipients with carbapenem-resistant Gram-negative bacilli infections after kidney transplantation treated with ceftazidime-avibactam: a retrospective study","volume":"14","author":"Zhang","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"key":"2026091106234526900_dlag200-B25","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1128\/AAC.01758-13","article-title":"A systematic review and meta-analyses show that carbapenem use and medical devices are the leading risk factors for carbapenem-resistant Pseudomonas aeruginosa","volume":"58","author":"Voor In \u2018t Holt","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2026091106234526900_dlag200-B26","doi-asserted-by":"publisher","first-page":"4311","DOI":"10.3748\/wjg.v24.i38.4311","article-title":"Management of bacterial and fungal infections in end stage liver disease and liver transplantation: current options and future directions","volume":"24","author":"Righi","year":"2018","journal-title":"World J Gastroenterol"},{"key":"2026091106234526900_dlag200-B27","volume-title":"English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR): Report 2023 to 2024","author":"UKHSA","year":"2024"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/5\/dlag200\/71030633\/dlag200.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/5\/dlag200\/71030633\/dlag200.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:23:53Z","timestamp":1789122233000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlag200\/8790378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlag200","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,1]]},"article-number":"dlag200"}}